Kairi Virus (KRIV) Nucleocapsid peptide
Description
Application Data
Description
-
Antigenic peptide of the viral capsid protein which encloses the nucleocapsids of Kairi Virus (KRIV)
Application Data
-
Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1200004 Antibody Kairi Virus (KRIV) Nucleocapsid peptide Antigen Peptide Kairi Virus (KRIV) Nucleocapsid peptide Protein ID UniProtKB - B8R6C1 Cross-Reactivity Kairi Virus Target Protein Species Kairi Virus Storage Stabilisers -20°C Specificity Protein Storage -20°C Citations Dunlop et al., (2018). Development of reverse genetics systems and investigation of host response antagonism and reassortment potential for Cache Valley and Kairi viruses, two emerging orthobunyaviruses of the Americas. PLOS Negl Trop Dis, 12(10), e0006884. PMID: 30372452
References Dunlop et al., (2018). Development of reverse genetics systems and investigation of host response antagonism and reassortment potential for Cache Valley and Kairi viruses, two emerging orthobunyaviruses of the Americas. PLOS Negl Trop Dis, 12(10), e0006884. PMID: 30372452
KRIV belongs to the Peribunyaviridae family of viruses (previously called Bunyaviridae). KRIV was first isolated from mosquito species in Trinidad including Aedes, Wyeomia, Culex and Psorophora spp. and has since been isolated from mosquitoes and vertebrates in Central and South America. Although between 6–18% of humans and up to 48% of horses have antibodies to KRIV, it does not cause any documented clinical disease symptoms in humans or animals. KRVI consists of three genome segments (called L [large], M [medium] and S [small]) which are encapsidated by the nucleocapsid (N) protein. These segments associate with the viral RNA-dependent RNA polymerase, the L protein, to form ribonucleoprotein complexes (RNP) termed nucleocapsids. RNPs are contained within a lipid envelope also containing the viral glycoproteins, Gn and Gc